Related Experiment Video
Updated: Nov 25, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
Prevalence of gastrointestinal symptoms in coronavirus disease 2019: a meta-analysis
E Merola1, F Armelao1, G de Pretis1
1Department of Gastroenterology, Azienda Provinciale per i Servizi Sanitari di Trento (APSS), Trento, Italy.
Insights
Gastrointestinal symptoms, including diarrhea, affect over 11% of COVID-19 patients. Viral RNA is present in stool samples, and asymptomatic cases may contribute to transmission.
Area of Science:
- Gastroenterology
- Infectious Diseases
- Public Health
Background:
- COVID-19 (coronavirus disease 2019) is a global pandemic.
- Gastrointestinal (GI) involvement in COVID-19 requires further investigation.
Purpose of the Study:
- To assess the frequency of GI manifestations in COVID-19 patients.
- To determine the prevalence of COVID-19 in stool samples.
- To evaluate the proportion of asymptomatic COVID-19 cases.
Main Methods:
- Systematic review and meta-analysis of studies published until March 25, 2020.
- Included 33 studies with 4434 COVID-19 patients.
- Utilized a random-effects model for pooled prevalence estimation.
Main Results:
- 11.51% of COVID-19 patients exhibited GI symptoms, with diarrhea being the most common (7.78%).
- COVID-19 positivity in stool samples was found in 41.50% of cases.
- 11.85% of COVID-19 patients were asymptomatic.
Conclusions:
- A significant number of COVID-19 patients present with GI symptoms.
- COVID-19 RNA is detectable in stool, indicating potential fecal-oral transmission.
- Asymptomatic individuals may play a role in viral spread.
Background And Study Aims:
The coronavirus disease 2019 (COVID-19) is a pandemic infection spreading worldwide at an unprecedented rate. Our aim was to assess the frequency of gastrointestinal (GI) involvement in COVID-19.
Patients And Methods:
We performed a systematic review and meta-analysis of all studies reporting clinical data about COVID-19 patients, published until 25th March 2020. The primary endpoint was the pooled prevalence of COVID-19 patients complaining of GI symptoms. Secondary endpoints were the pooled prevalence of cases with COVID-19 positive stool samples, and of asymptomatic COVID-19 patients. We used random-effects model for meta-analysis.
Results:
Thirty-three studies were included in the meta-analysis. Out of 4434 COVID-19 patients, the pooled prevalence of GI manifestations was 11.51% (95% CI : 8.16 to 15.35). The most frequent GI symptom was diarrhea (7.78% of cases ; 95% CI : 5.05 to 11.04), followed by nausea/vomiting (3.57% ; 95% CI : 1.87 to 5.80), poor appetite (2.39% ; 95%CI : 0.55 ; 5.46) and abdominal pain (0.78% ; 95% CI : 0.26 to 1.57). Positivity for COVID-19 in stool samples was observed in 41.50% (95% CI : 17.70 to 67.65) of cases. 11.85% (95% CI : 3.53 to 24.17) of COVID-19 patients remained asymptomatic.
Conclusions:
The present meta-analysis shows that a significant proportion of COVID-19 patients suffer from GI manifestations, as well as COVID-19 positivity in stool samples. Asymptomatic patients need to be considered a further potential route of viral transmission.
More Related Videos
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
06:55A High-throughput Platform for the Screening of Salmonella spp./Shigella spp.
Published on: November 7, 2018
Related Concept Videos
Assessment of the Gastrointestinal System I: Subjective Data
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Assessment of the Gastrointestinal System II: Health Perception Pattern
Health Perception Patterns
Health perception patterns offer valuable insights into a patient's lifestyle habits and how they may impact their GI health. These patterns include:
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...